BHC Shares Rise Following Solta's Acquisition of Shibo's Aesthetics Distribution Division
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2025
0mins
Should l Buy BHC?
Source: NASDAQ.COM
Bausch Health Acquisition: Bausch Health, Inc. shares rose 11% following the acquisition of Wuhan Shibo Zhenmei Technology, enhancing Solta Medical's distribution capabilities in China's growing aesthetics market.
Financial Performance: Bausch Health reported better-than-expected third-quarter results, with Solta Medical's revenues increasing by 25% year-over-year, although the company still faces significant long-term debt of $21 billion.
Market Positioning: The acquisition positions Solta Medical to meet rising demand for aesthetic treatments in China, improving operational efficiency and revenue potential in the region.
Stock Rankings: Bausch Health holds a Zacks Rank #3 (Hold), while other biotech stocks like CorMedix, Amicus Therapeutics, and ANI Pharmaceuticals are ranked #1 (Strong Buy), indicating stronger market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BHC
Wall Street analysts forecast BHC stock price to rise
4 Analyst Rating
0 Buy
4 Hold
0 Sell
Hold
Current: 5.580
Low
7.00
Averages
8.25
High
10.00
Current: 5.580
Low
7.00
Averages
8.25
High
10.00
About BHC
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bausch Health to Release Q1 2026 Financial Results on April 29
- Earnings Release Schedule: Bausch Health will release its Q1 2026 financial results after market close on April 29, 2026, which is expected to provide critical financial data and business updates to help investors assess the company's current financial health.
- Conference Call Details: The company will host a conference call and webcast at 5:00 p.m. U.S. EDT to discuss the financial results and provide business updates, ensuring that investors receive timely and important information.
- Investor Relations Materials: All relevant materials will be made available on the Bausch Health website's Investor Relations section prior to the start of the call, enhancing transparency and communication with investors.
- Company Background: Bausch Health is a global diversified pharmaceutical company focused on improving healthcare outcomes across various fields, including gastroenterology, neuroscience, and eye health, aiming to be a trusted global integrated healthcare company valued by patients and investors.
See More
Bausch Health to Release Q1 2026 Financial Results
- Earnings Release Schedule: Bausch Health will release its Q1 2026 financial results after market close on April 29, 2026, which is expected to provide critical financial data and business updates to help investors assess the company's operational performance.
- Conference Call Details: The company will host a conference call and webcast at 5:00 p.m. U.S. EDT, where it will discuss the financial results and answer investor questions, enhancing interaction and transparency with stakeholders.
- Investor Relations Materials: All relevant materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call, ensuring timely access to information and improving the efficiency of disclosures.
- Company Background: Bausch Health is a global diversified pharmaceutical company focused on delivering better healthcare outcomes across various fields, including gastroenterology, neuroscience, and eye health, showcasing its extensive influence in the healthcare industry.
See More
Bausch Health Launches New Laser Device in Canada
- Market Expansion: Bausch Health and Solta Medical have launched the Clear + Brilliant®Touch laser in Canada, marking a significant step in expanding their market share amid growing demand for non-invasive skin rejuvenation treatments.
- Technological Innovation: Approved by Health Canada in May 2025, the device features dual-wavelength laser technology that offers customizable treatment options suitable for various skin types and ages, enhancing treatment flexibility and effectiveness.
- Clinical Support: The Clear + Brilliant® laser platform is backed by over 15 clinical studies, effectively improving skin appearance and addressing early signs of aging, further solidifying Solta Medical's leadership in the global aesthetics market.
- Strategic Importance: This product launch not only strengthens Bausch Health's competitiveness in the aesthetics sector but also reflects the company's recognition of Canada's growth potential, aiming to meet the increasing consumer demand through innovative technology.
See More
ARESTIN® Celebrates 25th Anniversary Milestone
- Clinical Milestone: ARESTIN® (minocycline HCl) microspheres, the only FDA-approved locally applied antibiotic, has been clinically used for 25 years, aiding over one billion people in managing periodontal disease, highlighting its significance in oral health management.
- Innovative Treatment Method: Utilizing microsphere technology, ARESTIN delivers antibiotics directly into the periodontal pocket, gradually releasing the medication, which significantly enhances treatment efficacy and fills a gap in periodontal disease management, promoting non-surgical treatment advancements.
- Market Expansion Strategy: OraPharma's recent commercial expansion into Canada and Puerto Rico aims to improve treatment options for patients in these regions, reflecting the company's commitment to addressing unmet needs and further solidifying its market position in dentistry.
- Future Development Vision: Bausch Health executives emphasize that while celebrating past achievements, the focus will remain on innovation and deeper collaboration with the dental community to drive ongoing improvements in periodontal health.
See More
Bausch Health Reports Strong Q4 2025 Earnings with Strategic Acquisition
- Consistent Growth: Bausch Health achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, with full-year results exceeding guidance on all key metrics, demonstrating robust market performance and ongoing operational efficiencies.
- Strategic Acquisition: The company acquired Shibo, a full-service aesthetics distribution platform in China, on December 1, 2025, enhancing its direct commercial presence in one of the largest global aesthetics markets, which is expected to further boost market share and customer base.
- Financial Performance: Fourth-quarter revenue reached $1.391 billion, a 9% year-over-year increase, while adjusted EBITDA was $773 million, up 13%, reflecting strong performance in core products like Xifaxan and Thermage.
- Future Outlook: Management anticipates 2026 revenues between $5.25 billion and $5.4 billion, with adjusted EBITDA expected between $2.875 billion and $2.95 billion, indicating steady growth despite challenges from patent expirations and regulatory changes.
See More
Bausch Health (BHC) Q4 2025 Earnings Transcript
See More
Bausch Health to Release Q1 2026 Financial Results on April 29
- Earnings Release Schedule: Bausch Health will release its Q1 2026 financial results after market close on April 29, 2026, which is expected to provide critical financial data and business updates to help investors assess the company's current financial health.
- Conference Call Details: The company will host a conference call and webcast at 5:00 p.m. U.S. EDT to discuss the financial results and provide business updates, ensuring that investors receive timely and important information.
- Investor Relations Materials: All relevant materials will be made available on the Bausch Health website's Investor Relations section prior to the start of the call, enhancing transparency and communication with investors.
- Company Background: Bausch Health is a global diversified pharmaceutical company focused on improving healthcare outcomes across various fields, including gastroenterology, neuroscience, and eye health, aiming to be a trusted global integrated healthcare company valued by patients and investors.
See More
Bausch Health to Release Q1 2026 Financial Results
- Earnings Release Schedule: Bausch Health will release its Q1 2026 financial results after market close on April 29, 2026, which is expected to provide critical financial data and business updates to help investors assess the company's operational performance.
- Conference Call Details: The company will host a conference call and webcast at 5:00 p.m. U.S. EDT, where it will discuss the financial results and answer investor questions, enhancing interaction and transparency with stakeholders.
- Investor Relations Materials: All relevant materials will be made available on the Investor Relations section of the Bausch Health website prior to the start of the call, ensuring timely access to information and improving the efficiency of disclosures.
- Company Background: Bausch Health is a global diversified pharmaceutical company focused on delivering better healthcare outcomes across various fields, including gastroenterology, neuroscience, and eye health, showcasing its extensive influence in the healthcare industry.
See More
Bausch Health Launches New Laser Device in Canada
- Market Expansion: Bausch Health and Solta Medical have launched the Clear + Brilliant®Touch laser in Canada, marking a significant step in expanding their market share amid growing demand for non-invasive skin rejuvenation treatments.
- Technological Innovation: Approved by Health Canada in May 2025, the device features dual-wavelength laser technology that offers customizable treatment options suitable for various skin types and ages, enhancing treatment flexibility and effectiveness.
- Clinical Support: The Clear + Brilliant® laser platform is backed by over 15 clinical studies, effectively improving skin appearance and addressing early signs of aging, further solidifying Solta Medical's leadership in the global aesthetics market.
- Strategic Importance: This product launch not only strengthens Bausch Health's competitiveness in the aesthetics sector but also reflects the company's recognition of Canada's growth potential, aiming to meet the increasing consumer demand through innovative technology.
See More
ARESTIN® Celebrates 25th Anniversary Milestone
- Clinical Milestone: ARESTIN® (minocycline HCl) microspheres, the only FDA-approved locally applied antibiotic, has been clinically used for 25 years, aiding over one billion people in managing periodontal disease, highlighting its significance in oral health management.
- Innovative Treatment Method: Utilizing microsphere technology, ARESTIN delivers antibiotics directly into the periodontal pocket, gradually releasing the medication, which significantly enhances treatment efficacy and fills a gap in periodontal disease management, promoting non-surgical treatment advancements.
- Market Expansion Strategy: OraPharma's recent commercial expansion into Canada and Puerto Rico aims to improve treatment options for patients in these regions, reflecting the company's commitment to addressing unmet needs and further solidifying its market position in dentistry.
- Future Development Vision: Bausch Health executives emphasize that while celebrating past achievements, the focus will remain on innovation and deeper collaboration with the dental community to drive ongoing improvements in periodontal health.
See More
Bausch Health Reports Strong Q4 2025 Earnings with Strategic Acquisition
- Consistent Growth: Bausch Health achieved its 11th consecutive quarter of revenue and adjusted EBITDA growth, with full-year results exceeding guidance on all key metrics, demonstrating robust market performance and ongoing operational efficiencies.
- Strategic Acquisition: The company acquired Shibo, a full-service aesthetics distribution platform in China, on December 1, 2025, enhancing its direct commercial presence in one of the largest global aesthetics markets, which is expected to further boost market share and customer base.
- Financial Performance: Fourth-quarter revenue reached $1.391 billion, a 9% year-over-year increase, while adjusted EBITDA was $773 million, up 13%, reflecting strong performance in core products like Xifaxan and Thermage.
- Future Outlook: Management anticipates 2026 revenues between $5.25 billion and $5.4 billion, with adjusted EBITDA expected between $2.875 billion and $2.95 billion, indicating steady growth despite challenges from patent expirations and regulatory changes.
See More
Bausch Health (BHC) Q4 2025 Earnings Transcript
See More
